Association of the 4G/5G polymorphism in the promoter region of plasminogen activator inhibitor-1 with abdominal aortic aneurysms

Journal of Vascular Surgery

Volumn 31, Issue 5, 2000, Pages 1026-1032

  Rossaak, Jeremy I ^a   Van Rij, André M ^a   Jones, Gregory T ^a   Harris, Eugenie L ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX METALLOPROTEINASE; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESTRICTION ENDONUCLEASE; SERINE PROTEINASE; TISSUE PLASMINOGEN ACTIVATOR;

ABDOMINAL AORTA ANEURYSM; ARTICLE; CONTROLLED STUDY; FAMILIAL DISEASE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROMOTER REGION;

EID: 0034087967     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1067/mva.2000.104589     Document Type: Article

References (46)

1. Lederle FA, Johnson GR, Wilson SE, et al. Prevalence and associations of abdominal aortic aneurysm detected through screening: Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Group. Ann Intern Med 1997;126:441-9.
2. Collin J, Walton J. Is abdominal aortic aneurysm familial? Br Med J 1989;299:493.
3. Webster MW, Ferrell RE, St Jean PL, Majumder PP, Fogel SR, Steed DL. Ultrasound screening of first-degree relatives of patients with an abdominal aortic aneurysm. J Vasc Surg 1991; 13:9-14.
4. Bengtsson H, Norrgard O, Angquist KA, Ekberg O, Oberg L, Bergqvist D. Ultrasonographic screening of the abdominal aorta among siblings of patients with abdominal aortic aneurysms. Br J Surg 1989; 76:589-91.
5. Verloes A, Sakalihasan N, Koulischer L, Limet R. Aneurysms of the abdominal aorta: familial and genetic aspects in three hundred thirteen pedigrees. J Vasc Surg 1995;21:646-55.
6. Majumder PP, St Jean PL, Ferrell RE, Webster MW, Steed DL. On the inheritance of abdominal aortic aneurysm. Am J Hum Genet 1991;48:164-70.
7. Powell JT, Bashir A, Dawson S, et al. Genetic variation on chromosome 16 is associated with abdominal aortic aneurysm. Clin Sci (Colch) 1990;78:13-6.
8. Ramsbottom D, O'Neill A, Sexton DM, Gafoor RA, Bouchier-Hayes D, Croke DT. The cholesteryl ester transfer protein (CETP) locus as a candidate gene in abdominal aortic aneurysm. Clin Genet 1997;51:241-5.
9. Tromp G, Wu Y, Prockop DJ, et al. Sequencing of cDNA from 50 unrelated patients reveals that mutations in the triple-helical domain of type III procollagen are an infrequent cause of aortic aneurysms. J Clin Invest 1993;91:2539-45.
10. Jean-Claude J, Newman KM, Li H, Gregory AK, Tilson MD. Possible key role for plasmin in the pathogenesis of abdominal aortic aneurysms. Surgery 1994;116:472-8.
11. Reilly JM, Sicard GA, Lucore CL. Abnormal expression of plasminogen activators in aortic aneurysmal and occlusive disease. J Vasc Surg 1994;19:865-72.
12. Louwrens HD, Kwaan HC, Pearce WH, Yao JS, Verrusio E. Plasminogen activator and plasminogen activator inhibitor expression by normal and aneurysmal human aortic smooth muscle cells in culture. Eur J Vasc Endovasc Surg 1995;10:289-93.
13. Nagase H, Enghild JJ, Suzuki K, Salvesen G. Stepwise activation mechanisms of the precursor of matrix metalloproteinase 3 (stromelysin) by proteinases and (4-aminophenyl) mercuric acetate. Biochemistry 1990;29:5783-9.
14. Koklitis PA, Murphy G, Sutton C, Angal S. Purification of recombinant human prostromelysin: studies on heat activation to give high-Mr and low-Mr active forms, and a comparison of recombinant with natural stromelysin activities. Biochem J 1991;276:217-21.
15. Murphy G, Ward R, Gavrilovic J, Atkinson S. Physiological mechanisms for metalloproteinase activation. Matrix 1992;1(suppl):224-30.
16. Vine N, Powell JT. Metalloproteinases in degenerative aortic disease. Clin Sci (Colch) 1991;81:233-9.
17. Newman KM, Ogata Y, Malon AM, et al. Identification of matrix metalloproteinases 3 (stromelysin-1) and 9 (gelatinase B) in abdominal aortic aneurysm. Arteriosclerosis Thrombosis 1994;14:1315-20.
18. Newman KM, Malon AM, Shin RD, Scholes JV, Ramey WG, Tilson MD. Matrix metalloproteinases in abdominal aortic aneurysm: characterization, purification, and their possible sources. Connect Tissue Res 1994;30:265-76.
19. Dawson S, Hamsten A, Wiman B, Henney A, Humphries S. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arteriosclerosis Thrombosis 1991;11:183-90.
20. Humphries SE, Panahloo A, Montgomery HE, Green F, Yudkin J. Gene-environment interaction in the determination of levels of haemostatic variables involved in thrombosis and fibrinolysis. Thromb Haemost 1997;78:457-61.
21. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993;268:10739-45.
22. Eriksson P, Kallin B, van't Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995;92:1851-5.
23. Rossaak JI, Jones GT, Hill TM, Phillips LV, Harris EL, van Rij AM. Familial incidence of abdominal aortic aneurysms [abstract]. Aust N Z J Surg 1998;68(suppl):A158.
24. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
25. Margaglione M, Grandone E, Cappucci G, et al. An alternative method for PAI-1 promoter polymorphism (4G/ 5G) typing. Thromb Haemost 1997;77:605-6.
26. Pearce WH, Sweis I, Yao JS, McCarthy WJ, Koch AE. Interleukin-1 beta and tumor necrosis factor-alpha release in normal and diseased human infrarenal aortas. J Vasc Surg 1992;16:784-9.
27. Smith FB, Lee AJ, Rumley A, Fowkes FG, Lowe GD. Tissue-plasminogen activator, plasminogen activator inhibitor and risk of peripheral arterial disease. Atherosclerosis 1995;115:35-43.
28. Papademetriou V, Narayan P, Rubins H, Collins D, Robins S. Influence of risk factors on peripheral and cerebrovascular disease in men with coronary artery disease, low high-density lipoprotein cholesterol levels, and desirable low-density lipoprotein cholesterol levels: HIT Investigators: Department of Veterans Affairs HDL Intervention Trial. Am Heart J 1998;136:734-40.
29. Smith FC, Grimshaw GM, Paterson IS, Shearman CP, H amer JD. Ultrasonographic screening for abdominal aortic aneurysm in an urban community. Br J Surg 1993;80:1406-9.
30. Kanagasabay R, Gajraj H, Pointon L, Scott RA. Co-morbidity in patients with abdominal aortic aneurysm. J Med Screen 1996;3:208-10.
31. Mattes E, Davis TM, Yang D, Ridley D, Lund H, Norman PE. Prevalence of abdominal aortic aneurysms in men with diabetes [see comments]. Med J Aust 1997;166:630-3.
32. Mansfield MW, Stickland MH, Grant PJ. PAI-1 concentrations in first-degree relatives of patients with non-insulin-dependant diabetes: metabolic and genetic associations. Thromb Haemost 1997;77:357-61.
33. Wilmink AB, Quick CR. Epidemiology and potential for prevention of abdominal aortic aneurysm. Br J Surg 1998;85:155-62.
34. Alcorn HG, Wolfson SK Jr, Sutton-Tyrrell K, Kuller LH, O'Leary D. Risk factors for abdominal aortic aneurysms in older adults enrolled in the cardiovascular health study. Arterioscler Thromb Vasc Biol 1996;16:963-70.
35. Sabiston DC. Aortic abdominal aneurysms. In: Sabiston DC, ed. Textbook of surgery: the biological basis of modern surgical practice. Philadelphia: W B Saunders; 1997. p. 1665-72.
36. Tilson MD, Stansel HC. Differences in results for aneurysm vs occlusive disease after bifurcation grafts: results of 100 elective grafts. Arch Surg 1980;115:1173-5.
37. Ossei-Gerning N, Mansfield MW, Stickland MH, Wilson IJ, Grant PJ. Plasminogen activator inhibitor-1 promoter 4G/ 5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography. Arterioscler Thromb Vasc Biol 1997;17:33-7.
38. Margaglione M, Cappucci G, d'Addedda M, et al. PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis: relation to environmental and genetic determinants. Arterioscler Thromb Vasc Biol 1998;18:562-7.
39. Sugano T, Tsuji H, Masuda H, et al. Plasminogen activator inhibitor-1 promoter 4G/ 5G genotype is not a risk factor for myocardial infarction in a Japanese population. Blood Coagul Fibrinolysis 1998;9:201-4.
40. Burzotta F, Di Castelnuovo A, Amore C, et al. 4G/ 5G promoter PAI-1 gene polymorphism is associated with plasmatic PAI-1 activity in Italians: a model of gene-environment interaction. Thromb Haemost 1998;79:354-8.
41. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Miletich JP. Arterial and venous thrombosis is not associated with the 4G/ 5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation 1997;95:59-62.
42. Takei H, Ishikawa S, Otaki A, et al. Screening for abdominal aortic aneurysm and occlusive peripheral vascular disease in Japanese residents. Surg Today 1995;25:608-11.
43. Mannucci PM, Mari D, Merati G, et al. Gene polymorphisms predicting high plasma levels of coagulation and fibrinolysis proteins: a study in centenarians. Arterioscler Thromb Vasc Biol 1997;17:755-9.
44. Mansfield MW, Stickland MH, Grant PJ. Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non-insulin-dependent diabetes mellitus. Thromb Haemost 1995;74:842-7.
45. Mansfield MW, Stickland MH, Grant PJ. Plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulin-dependent diabetes. Thromb Haemost 1995;74:1032-4.
46. Panahloo A, Mohamed-Ali V, Lane A, Green F, Humphries SE, Yudkin JS. Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes 1995;44:37-42.